Showing 4481-4490 of 8485 results for "".
- SENTE Launches Collaborations with Galderma, The HydraFacial Companyhttps://practicaldermatology.com/news/sente-launches-collaborations-with-galderma-the-hydrafacial-company/2457546/New strategic collaborations are intended to broaden the reach of SENTÉ and further expand their disruptive professional grade skin care product portfolio, the company says. Both collaborations will offer consumers the opportunity
- Sinclair Pharma Announces Leadership Changeshttps://practicaldermatology.com/news/sinclair-pharma-announces-leadership-changes/2457491/Sinclair Pharma Limited reported that effective at the end of the year, Doug Abel has resigned his position as Head of North America and President of Silhouette Lift, Inc., to lead a new aesthetic venture and has licensed the US sales and marketing rights to the Refine Support System from Sinclai
- Exuviance Introduces HA100 Micro-Filler Regimenhttps://practicaldermatology.com/news/exuviance-introduces-ha100-micro-filler-regimen/2457502/Exuviance is launching HA100 Micro-Filler Regimen, a two-step beauty regimen featuring new Micro-Cone Patches that delivers 1
- Sonoma Pharmaceuticals Launches New Ceramax Skin Barrier Lotionhttps://practicaldermatology.com/news/sonoma-pharmaceuticals-launches-new-ceramax-skin-barrier-lotion/2457504/Sonoma Pharmaceuticals, Inc. has launched a new Ceramax™ Skin Barrier Lotion that complements Sonoma’s current Ceramax Skin Barrier Cream. Both Ceramax products contain skin-enriching technology that helps manage dry itchy skin,
- Cutanea Life Sciences Launches Xepi Creamhttps://practicaldermatology.com/news/cutanea-life-sciences-launches-xepi-cream-1/2457512/Cutanea Life Sciences, Inc. has launched Xepi™ (ozenoxacin) Cream, 1% for the treatment of impetigo in adult and pediatric patients two months of age or older. Xepi is a non-fluorinated topical quinolone indicated for the treatment of impetigo due to Staphylococcus aureus
- Ortho Dermatologics Gears Up to Launch Bryhali Lotion for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-gears-up-to-launch-bryhali-lotion-for-plaque-psoriasis/2457514/Ortho Dermatologics expects to start distribution of Bryhali (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final approval from the U.S. Food and Drug Administration (FDA) for Bryhali Lotion on Nov. 6, 201
- FDA Approves Galderma's Restylane Lyft for Midface Injection Via Cannulahttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-lyft-for-midface-injection-via-cannula/2457518/The U.S. Food and Drug Administration (FDA) has approved the use of Galderma’s Restylane Lyft with a small, blunt-tip cannula for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. This approval is the second ca
- Mayne Pharma Acquires FDA-approved Halobetasol Foamhttps://practicaldermatology.com/news/mayne-pharma-acquires-fda-approved-halobetasol-foam/2457520/Mayne Pharma has acquired the US and Australian rights to halobetasol foam 0.05% for an investment of up to $32 million (comprising $10 million in cash up front, $5 million at commercial launch plus continge
- Milestone Alert: Galderma's ASPIRE Rewards Program Hits the Million Member Markhttps://practicaldermatology.com/news/milestone-alert-galdermas-aspire-rewards-program-hits-the-million-member-mark/2457530/Galderma Laboratories, L.P’s ASPIRE Rewards program has reached the one million member milestone. ASPIRE is a loyalty program for consumers and aesthetic providers who use Galderma aesthetic injectab
- LA BioMed Team to Study Treatments for Antibiotic-Resistant Skin Infectionshttps://practicaldermatology.com/news/la-biomed-team-to-study-treatments-for-antibiotic-resistant-skin-infections/2457533/Investigators from LA BioMed have scored a $5.3M grant from the National Institutes of Health to study the effectiveness of treatments for antibiotic-resistant skin infections. The study,